What is ACAD's current stock price?

ACAD (ACADIA Pharmaceuticals Inc.) is currently trading at $21.10 with a market cap of $3.61B.

What sector is ACADIA Pharmaceuticals Inc. in?

ACADIA Pharmaceuticals Inc. (ACAD) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is ACAD a good stock to buy?

Analysts have a Buy consensus on ACAD with a price target of $34.78. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

ACAD ACADIA Pharmaceuticals Inc.

Healthcare

$21.10-1.03%ClosedMarket Cap: $3.61B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

9.48

PEG

0.13

P/B

2.88

P/S

3.30

EV/EBITDA

32.34

DCF Value

$-37.33

FCF Yield

5.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

91.5%

Operating Margin

7.4%

Net Margin

34.3%

ROE

35.6%

ROA

23.4%

ROIC

6.2%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$268.1M	$3.6M	$—
Q4 null	$284.0M	$273.6M	$—
FY null	$1.07B	$391.0M	$—
Q3 null	$278.6M	$71.8M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$34.78

Target (Median)

$35.00

Target Range

$29.00 - $40.00

4 Strong Buy12 Buy4 Hold1 Sell0 Strong Sell

CitigroupBuy

2026-05-08

B of A SecuritiesBuy

2026-03-25

JP MorganOverweight

2026-03-04

RBC CapitalOutperform

2026-02-26

StifelHold

2026-02-26

Trading Activity

Insider Trades

View All

Schneyer Mark C.officer: EVP, CHIEF FINANCIAL OFFICER

SellTue May 05

Schneyer Mark C.officer: EVP, CHIEF FINANCIAL OFFICER

SellTue May 05

Kihara Jamesofficer: PRINCIPAL ACCOUNTING OFFICER

SellTue May 05

Kihara Jamesofficer: PRINCIPAL ACCOUNTING OFFICER

SellTue May 05

Schneyer Mark C.officer: EVP, CHIEF FINANCIAL OFFICER

SellTue Apr 07

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.86

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Peers

DYN